immunotherapy response

A new study published in Frontiers in Immunology shows that doctors may be able to tell which patients with malignant pleural mesothelioma will respond better to immunotherapy. If doctors can tell which patients will benefit from immunotherapy, they can create better treatment plans for this aggressive type of cancer. Treatment Options Malignant pleural mesothelioma (MPM) is a cancer that develops in the lining of the lungs. It is caused by asbestos and is tough to treat. MPM is a rare cancer, and the standard therapies are limited. This usually involves surgery, radiation, and chemotherapy. Mesothelioma patients can move from one type of treatment to another and, if their doctors agree, can sometimes use them in combination. Even with treatment, the…